Treatment of chronic hepatitis C with PEGylated interferon and ribavirin

[1]  C. Trautwein,et al.  Treatment of acute hepatitis C with interferon alfa-2b. , 2001, The New England journal of medicine.

[2]  Kenneth Koury,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .

[3]  J. Crowe,et al.  The natural course of hepatitis C virus infection after 22 years in a unique homogenous cohort: spontaneous viral clearance and chronic HCV infection , 2001, Gut.

[4]  J. Montaner,et al.  Antiretroviral therapy for previously treated patients. , 2001, The New England journal of medicine.

[5]  E. Schiff,et al.  A randomized, double‐blind trial comparing pegylated interferon alfa‐2b to interferon alfa‐2b as initial treatment for chronic hepatitis C , 2001, Hepatology.

[6]  E. Meili,et al.  Ribavirin and interferon alpha-2b combination treatment of chronic hepatitis C is effective in patients with clotting disorders , 2001 .

[7]  Jian Yu,et al.  Pegylated (40kDa) interferon alfa-2a (PEGASYS®) in combination with ribavirin: Efficacy and safety results from a phase III, randomized, actively-controlled, multicenter study , 2001 .

[8]  A K Manatunga,et al.  Paroxetine for the prevention of depression induced by high-dose interferon alfa. , 2001, The New England journal of medicine.

[9]  Zhi-xin Xu,et al.  Rational design of a potent, long-lasting form of interferon: a 40 kDa branched polyethylene glycol-conjugated interferon alpha-2a for the treatment of hepatitis C. , 2001, Bioconjugate chemistry.

[10]  A. Tamori,et al.  Prevention of hepatocellular carcinoma in patients with chronic active hepatitis C and cirrhosis , 2001, The Lancet.

[11]  S. Goodman,et al.  Interferon and ribavirin vs interferon alone in the re-treatment of chronic hepatitis C previously nonresponsive to interferon: A meta-analysis of randomized trials. , 2001, JAMA.

[12]  M. Shiffman,et al.  Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. , 2000, The New England journal of medicine.

[13]  J. Reichen,et al.  Peginterferon alfa-2a in patients with chronic hepatitis C. , 2000, The New England journal of medicine.

[14]  Samir K. Gupta,et al.  Pegylated interferon‐α2b: Pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data , 2000 .

[15]  C. Gibbs,et al.  Combination therapy with lamivudine and famciclovir for chronic hepatitis B–infected Chinese patients: A viral dynamics study , 2000, Hepatology.

[16]  F. Berr,et al.  Low frequency of cirrhosis in a hepatitis C (genotype 1b) single‐source outbreak in germany: A 20‐year multicenter study , 2000, Hepatology.

[17]  L. Seeff,et al.  45-Year Follow-up of Hepatitis C Virus Infection in Healthy Young Adults , 2000, Annals of Internal Medicine.

[18]  C. Garret,et al.  A randomized, controlled trial of maintenance interferon therapy for patients with chronic hepatitis C virus and persistent viremia. , 1999, Gastroenterology.

[19]  E. Kenny‐Walsh.  Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group. , 1999, The New England journal of medicine.

[20]  M. Vidaud,et al.  Modeling the impact of interferon alfa treatment on liver fibrosis progression in chronic hepatitis C: a dynamic view. The Multivirc Group. , 1999, Gastroenterology.

[21]  J. Hoefs,et al.  Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. , 1998, The New England journal of medicine.

[22]  William M. Lee,et al.  Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. , 1998, The New England journal of medicine.

[23]  P. Marcellin,et al.  Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus , 1998, The Lancet.

[24]  J. Hoofnagle,et al.  10‐year follow‐up after interferon‐α therapy for chronic hepatitis C , 1998 .

[25]  M. Manns,et al.  [Is combination therapy of chronic hepatitis C with interferon alpha and ribavirin in primary interferon nonresponders indicated?--An analysis of personal experiences and review of the literature]. , 1998, Zeitschrift fur Gastroenterologie.

[26]  A. Neumann,et al.  Dose‐dependent acute clearance of hepatitis C genotype 1 virus with interferon alfa , 1997, Hepatology.

[27]  S. Seki,et al.  Randomised trial of effects of interferon-α on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis , 1995, The Lancet.

[28]  Willis C. Maddrey,et al.  EASL International Consensus Conference on hepatitis C. Paris, 26-27 February 1999. Consensus statement. , 1999, Journal of hepatology.